Abstract

Cervical cancer is a major public health concern, particularly in low- and middle-income countries where screening programs are less accessible. The Papanicolaou (Pap) test has been instrumental in reducing the incidence and mortality of cervical cancer worldwide. Abnormal Pap test results serve as an early warning system, enabling timely identification and management of precancerous lesions or early-stage cervical cancer. This article explores the role of abnormal Pap tests in cervical cancer prevention, examining their significance in screening programs, the factors influencing test results, and their impact on treatment and prognosis. The discussion underscores the necessity of public health strategies to improve access to and understanding of cervical screening programs globally.